Selected Start-Ups (02/01)
Executive Summary
In Vivo summarizes the technology of several recently founded companies: Clinsights Inc. provides web-based post-market clinical and sales support for medical device and pharmaceutical companies and physicians. CombinatoRx Inc. hopes to develop the next generation of pharmaceuticals using new theories of how therapeutics should interact with the complex components of cells. Gyros AB has developed technology for miniaturizing and integrating routine and non-routine laboratory processes on disposable CDs. Innovative Drug Delivery Systems Inc. will develop and commercialize unique nasally administered compounds to treat acute and chronic pain and their associated symptoms. PhytaGenics will use its proprietary rapid, high-volume transgenic production technology to create recombinant biopharmaceutical proteins in plants. StemCo Biomedical Inc.'s stem cell platform is capable of identifying and isolating healthy stem cells from contaminating cells, and can be used in repopulating blood systems or regenerating organs and tissue.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.